Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 29, 2026
TickeronGET DAILY SIGNALS
Why Is Accuray Incorporated (ARAY) Stock Down -15.28% Today?

Why Is Accuray Incorporated (ARAY) Stock Down -15.28% Today?

Key Takeaways

  • ARAY shares fell roughly 15.28% in early trading Tuesday, last around $0.254 versus a prior close of $0.2998.
  • The decline follows Monday's roughly 39% surge, which was sparked by a new imaging collaboration with Samsung HME America (Samsung NeuroLogica).
  • Today's move reflects profit-taking and a "buy the rumor, sell the news" unwind after a speculative spike on record volume.
  • Investors are refocusing on fundamentals: persistent losses, negative margins, a planned reverse stock split, and a prior Nasdaq delisting warning.
  • Traders are watching whether the pullback stabilizes and whether trading volume normalizes from Monday's extreme levels.

Opening Summary

Accuray Incorporated (ARAY) is a Madison, Wisconsin-based radiation oncology company that develops, manufactures, and services precision radiation therapy systems, including the CyberKnife robotic radiosurgery platform and the TomoTherapy/Radixact platform. In Tuesday's session, the stock fell 15.28% to approximately $0.254, down from a prior closing price of $0.2998. The pullback comes one day after the shares skyrocketed nearly 40% on the announcement of a partnership aimed at adding advanced volumetric imaging to the CyberKnife system — a sharp reversal that markets attribute primarily to profit-taking and a reassessment of the deal's near-term commercial impact.

Profit-Taking After a Samsung-Fueled Surge

The dominant catalyst for today's decline is the unwinding of Monday's explosive rally. On Saturday, ARAY announced a collaboration with Samsung HME America, operating as Samsung NeuroLogica, to pursue advanced volumetric imaging capabilities for its CyberKnife platform. The news, unveiled alongside the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, sent the stock up approximately 39% on Monday, with intraday gains pushing shares as high as $0.382 on volume of more than 370 million shares — a dramatic departure from its roughly one-million-share daily average.

However, the partnership carries meaningful caveats. Accuray and Samsung NeuroLogica said the collaboration would progress through "phased development activities," and no commercial product has been announced. With future developments dependent on ongoing technical, clinical, and commercial evaluation and regulatory requirements, some traders moved to lock in gains from the rapid advance, driving the stock lower Tuesday morning.

Fundamental and Balance-Sheet Headwinds

Beneath the headline news, ARAY continues to face a difficult financial backdrop that makes sharp speculative moves prone to reversals. The company has reported declining revenue and persistent net losses, with negative operating margins and a trailing twelve-month loss per share of roughly $0.40. Its debt-to-equity ratio remains elevated, and earlier this year Accuray unveiled a $55 million recapitalization with its largest lender and shareholder, TCW, which included a debt-for-preferred-stock exchange and a planned reverse stock split intended to regain Nasdaq listing compliance after a prior delisting warning. These dilution and liquidity concerns resurfaced as the market looked beyond Monday's partnership enthusiasm.

Market Context and Trading Activity

The move reflects highly elevated volatility rather than a broad sector downturn. Monday's trading turnover of hundreds of millions of shares dwarfed ARAY's typical volume, and Tuesday's pullback occurred against a backdrop of extraordinary price swings — the stock's Monday range spanned more than 45% from trough to peak. Technical measures were stretched after the rally, leaving the shares vulnerable as momentum traders and short-term speculators exited. The decline is largely idiosyncratic to the stock, driven by the post-announcement re-pricing rather than a coordinated move across the medical-device or radiation-oncology peer group.

What Comes Next for ARAY

Looking ahead, investors will monitor whether ARAY can hold recent levels and whether the Samsung NeuroLogica collaboration translates into tangible development milestones. Key dates include the company's next earnings report, expected in early November, which will provide a clearer view of revenue trends and progress on its transformation plan. The status of the planned reverse stock split and any steps toward regaining Nasdaq compliance remain central risks, as does continued dilution from the recapitalization. With limited analyst coverage and a consensus view of "Hold," the stock is likely to remain volatile as it balances innovation-driven optimism against a challenged balance sheet.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are among the strongest performers under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each differing by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots to discover which automated strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARAY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ARAY sees MACD Histogram crosses below signal line

ARAY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 09, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 43 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARAY as a result. In 86 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ARAY entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ARAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.315) is normal, around the industry mean (4.142). P/E Ratio (-0.275) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (2.060) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.070) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ARAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of medical equipment

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1240 Deming Way
Phone
+1 608 824-2800
Employees
809
Web
https://www.accuray.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.